For instance, CD70 was recently identified as a promising target for CAR-T cell therapy in AML because of its selective expression on both leukemic blasts and leukemic stem cells [85], providing a rationale for targeted therapy in AML without adversely affecting normal hematopoiesis [86]. Here, CD70 is linked to acute myeloid leukemia.